Friday September 25, 2015 0 comments
WESTMINSTER -- Surefire Medical Inc. today announced the launch of its new Precision targeted delivery infusion system for direct-to-tumor embolization procedures.
The new technology will be displayed at the Cardiovascular and Interventional Radiological Society of Europe’s 2015 Scientific Meeting in Lisbon, Portugal Sept. 26-30.
Surefire infusion systems are used by interventional radiologists and interventional oncologists in minimally invasive primary and secondary liver cancer treatments.
“Chemo and radioembolization techniques are becoming valuable treatment options in selected patients with unresectable liver tumors,” said radiology professor G. Maleux at the University Hospitals in Leuven, Belgium.
“The Precision catheter provides us with a new interventional tool to safely and effectively deliver drug-eluting and yttrium-90 microspheres within the tumor.”
Surefire said the Precision addresses a clear need in the ability to treat primary liver cancers -- of which 80 percent are inoperable -- and may help lower the overall costs of treatment.
A recent prospective clinical trial showed the Surefire infusion technology increased drug delivery into tumors by up to 90 percent and reduced non-target delivery to healthy tissue.
The Precision has received the CE Mark and FDA clearance, Surefire said.
“The drug delivery system matters far more than previously thought,” said James E. Chomas, Surefire’s president and CEO. “Primary liver cancers often contain regions of high pressure and no blood flow, creating a barrier to drug delivery.
“The Surefire Precision device uniquely overcomes this obstacle by controlling pressure during drug delivery such that drug penetration into tumors increases significantly.”